Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

First Patient Dosed in the Phase I/II Study of UC1010 for PMDD Patients

Published: Monday, May 27, 2013
Last Updated: Monday, May 27, 2013
Bookmark and Share
First patient has been dosed with UC1010 in a double-blind, multicenter study.

Umecrine Mood AB has announced that dosing has been initiated in a randomized Phase I/II study of UC1010 for the treatment of patients with premenstrual dysphoric disorder (PMDD).

Umecrine Mood is part of the Karolinska Development portfolio.

Most women experience some form of symptoms the days before menstruation but in about five percent of young and middle-aged women, the symptoms are so severe that they are considered to be suffering from PMDD.

This means that the symptoms in a debilitating way affect daily life and relationships to other people.

"The symptoms occur due to that a breakdown product of a sex hormone affect the brain's emotional center. Umecrine Mood is the first company to successfully develop compounds that are proven to reduce the activity of the breakdown product in healthy individuals. Now we take the next step to evaluate the safety and efficacy of our drug candidate in patients", says Karin Ekberg, CEO of Umecrine Mood.

The first patient has now been dosed with UC1010 in a double-blind, multicenter study in which the safety and efficacy of the product will be evaluated in a total of 120 individuals.

Principal Investigator is Professor Marie Bixo, Institute of Clinical Research and Education, Södersjukhuset, Karolinska Institutet.

"The currently available treatment of PMDD is primarily antidepressant drugs, which are not always effective and often cause side effects", says Torbjörn Bjerke, CEO of Karolinska Development AB.

Bjerke continued, "There is no doubt that these women are in need of an effective and targeted treatment, nor that the health economic benefits of being able to help the patient group would be significant."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dilaforette Initiates Phase II Clinical Trial with Sevuparin in SCD
A multi-center, double-blind, placebo-controlled study in patients experiencing vaso-occlusive crisis.
Wednesday, October 21, 2015
Dilafor Enters into a License and Partnership Agreement with Lee’s Pharmaceutical
Dilafor grants the right to manufacture, develop and commercialize tafoxiparin to Lee's Pharmaceutical.
Friday, February 21, 2014
Pergamum Announces Final Data from Phase I/II Study of LL-37
Phase I/II trial of LL-37 for treatment of patients with chronic leg ulcers.
Thursday, October 10, 2013
Lipidor Reports Positive Clinical Phase I/II Data in Psoriasis
Company is developing AKVANO®/calcipotriol for the treatment of psoriasis vulgaris.
Thursday, August 29, 2013
Pharmanest Meets All Efficacy and Safety End Points in Phase II Study of SHACT
Data show that SHACT is effective in reducing pain during IUD insertion.
Monday, August 05, 2013
Pergamum Reports Positive Data from Phase II Clinical Trial of PXL-01
Follow-up data from the Phase II clinical trial for prevention of post-surgical adhesions.
Thursday, June 27, 2013
Pharmanest Initiates Phase I Trial with SHACT
Trial is expected to enroll 15 patients and the study will be conducted at the Karolinska University Hospital.
Monday, October 15, 2012
Pergamum Reports Top Line Phase II-data from the Clinical Trial of PXL-01
The final Phase II report is expected to be published in the third quarter 2012.
Monday, August 06, 2012
Pharmanest Initiates Phase II Study of SHACT
Goal of the study is to evaluate the effect of SHACT in connection with IUD insertion in women.
Tuesday, June 19, 2012
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos